search

Active clinical trials for "Macular Degeneration"

Results 741-750 of 1337

CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl)

AMDExudative Macular Degeneration

The main objective of this study is to analyze a new noninvasive imaging examination, OCT angiography, in the evaluation of neovascular remodeling and early signs of recurrence of wet AMD undergoing treatment on OCTA and to correlate OCTA findings with SD-OCT findings.

Active27 enrollment criteria

Surgical Management of Optic Disc Pit Maculaopathy

Optic Disc Structural AnomalyMaculopathy

To evaluate the anatomical and functional results of pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.

Completed1 enrollment criteria

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)...

Age Related Macular Degeneration

The investigators hope to determine if "wet" AMD patients differ from patients with "dry" AMD or normal eyes in the production of anti-retinal pigment epithelium (anti-RPE) or anti-retinal antibody formation. To explain: the immune system can make antibodies that attack our own cells, specifically the RPE and the retina. Normally the RPE and retinal cells are ignored by the immune system, but when disease occurs, immune reactions can occur, making an autoantibody that can attack the patient's own cells and make things worse. This production of autoantibodies that react with our own RPE and retinal cells is what the investigators want to test in this proposal to see if they may contribute to, or are responsible for, a poor response to treatment. The investigators also want to know how those patients who initially respond to the standard-of-care treatment, ranibizumab injections, differ in the production of anti-RPE or anti-retinal antibody formation, from those patients who do not respond initially after 4 consecutive injections.

Completed24 enrollment criteria

Transcorneal Electrical Stimulation Therapy for Retinal Disease

Retinitis PigmentosaMacula Off9 more

Transcorneal stimulation may enable neurons to survive degeneration processes via enhanced secretion of neurotrophic substances and direct stimulation of neurons.

Completed3 enrollment criteria

Dry Age-Related Macular Degeneration (AMD) Treatment With Rheopheresis Trial

Dry Age Related Macular Degeneration

Purpose is to evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.

Completed19 enrollment criteria

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

Nonexudative Age-related Macular Degeneration

The purpose of this study is to evaluate clinical outcomes of Photobiomodulation treatment on patients with dry Age Related Macular Degeneration (AMD). Photobiomodulation is the use of non thermal, non laser light of specific wavelengths and energy directly on the eye to improve retinal function and delay AMD progression. This is a prospective 2 center phase 2 clinical pilot study with no placebo group.

Completed16 enrollment criteria

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal...

Macular DegenerationMaculopathy1 more

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Completed1 enrollment criteria

Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)...

Macular Degeneration

This is a Phase III, open-label, multicenter extension study of intravitreally administered ranibizumab in subjects with primary or recurrent subfoveal choroidal neovascularization (CNV) secondary to AMD who have completed the treatment phase of a Genentech sponsored Phase I or Phase I/II ranibizumab protocol (FVF1770g, FVF2128g, or FVF2425g).

Completed20 enrollment criteria

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD)...

Wet Age-related Macular Degeneration

In this observational study researchers want to learn more about changes in visual acuity (clarity of vision) with proactive flexible treatments over time in patients suffering from wet age-related macular degeneration (wAMD) after decision to treat with Aflibercept (Eylea) was made. Wet AMD is an eye disease that progressively destroys the macula, the central portion of the retina, impairing central vision.

Active11 enrollment criteria

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With...

Macular Degeneration

The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).

Completed41 enrollment criteria
1...747576...134

Need Help? Contact our team!


We'll reach out to this number within 24 hrs